Tag Archives: Prof Olav Mella

Intravenous cyclophosphamide in ME/CFS. An open-label phase II study

Posted on 05/04/2020 by wames

Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study by Ingrid G Rekeland, Alexander Fosså, Asgeir Lande, Irini Ktoridou-Valen, Kari Sørland, Mari Holsen, Karl J Tronstad, Kristin Risa, Kine Alme, Marte K Viken, Benedicte A Lie, Olav … Continue reading →

Posted in News | Tagged , , , , , , , , , , , , , , , , , | Comments Off on Intravenous cyclophosphamide in ME/CFS. An open-label phase II study

Human Leukocyte Antigen alleles associated with ME/CFS

Posted on 04/01/2020 by wames

Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), by Asgeir Lande, Øystein Fluge, Elin B Strand, Siri T Flåm, Daysi D Sosa, Olav Mella, Torstein Egeland, Ola D Saugsta, Benedicte A Lie, Marte K Viken in Scientific … Continue reading →

Posted in News | Tagged , , , , , , , , , , , , , | Comments Off on Human Leukocyte Antigen alleles associated with ME/CFS

B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results

Posted on 04/03/2019 by wames

B-lymphocyte depletion in patients With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: a randomized, double-blind, placebo-controlled trial by Oystein Fluge, Ingrid G. Rekeland, Katarina Lien, Hanne Thurmer, Petter C. Borchgrevink, Christoph Schafer, Kari Sorland, Jorg Assmus, Irini Ktoridou-Valen, Ingrid Herder, Merethe E. … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on B-Lymphocyte depletion in patients with ME/CFS: the final rituximab trial results

Immunosignature analysis of ME/CFS – promising diagnostic biomarker

Posted on 10/15/2018 by wames

Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Oliver P Günther, Jennifer L Gardy, Phillip Stafford, Øystein Fluge, Olav Mella, Patrick Tang, Ruth R Miller, Shoshana M Parker, Stephen A Johnston, David M Patrick in Molecular Neurobiology (2018) pp 1-9 [Published online: … Continue reading →

Posted in News | Tagged , , , , , , , , , , , , , | Comments Off on Immunosignature analysis of ME/CFS – promising diagnostic biomarker

Norwegian rituximab trial reports negative results

Posted on 11/28/2017 by wames

The Norwegian Rituximab trial reports negative results ahead of the publication of the full results. Attempts are now under way to determine the best way forward in understanding what has been learned and how to find out which patients may still benefit from … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Norwegian rituximab trial reports negative results

Norwegian Rituximab studies update

Posted on 11/03/2017 by wames

Helse Bergen blog post, 29 Sep 29017: RituxME B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome (“RituxME”) ​RituxME is a multicentre study conducted in five study centres in Norway: the Oncology Department at Haukeland University … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on Norwegian Rituximab studies update

Fuel shortage: Norwegian study expands on energy problem in ME/CFS

Posted on 01/09/2017 by wames

Health rising blog post, by Cort Johnson, 27 Dec 2016: Fuel shortage: Norwegian study Expands on Energy Problem in Chronic Fatigue Syndrome (ME/CFS) Fluge and Mella seem to be working at almost lightning speed. Besides managing their huge Rituximab study … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Fuel shortage: Norwegian study expands on energy problem in ME/CFS

Metabolic profiling indicates impaired pyruvate dehydrogenase function in ME/CFS

Posted on 12/23/2016 by wames

Research abstract: Myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) is a debilitating disease of unknown etiology, with hallmark symptoms including postexertional malaise and poor recovery. Metabolic dysfunction is a plausible contributing factor. We hypothesized that changes in serum amino acids may disclose … Continue reading →

Posted in News | Tagged , , , , , , | Comments Off on Metabolic profiling indicates impaired pyruvate dehydrogenase function in ME/CFS

Mella finds hypometabolic state in ME/CFS

Posted on 10/17/2016 by wames

Health rising blog post, by Cort Johnson, 15 October 2016: Another Hypometabolic Signature Found Fluge and Mella are best known for their Rituximab work, but just last week Mella reported that they’d found a hypometabolic state in ME/CFS as well. … Continue reading →

Posted in News | Tagged , , , , , , , , , | Comments Off on Mella finds hypometabolic state in ME/CFS

New rituximab trial results from Norway

Posted on 08/22/2016 by wames

Research abstract: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in … Continue reading →

Posted in News | Tagged , , , , , | Comments Off on New rituximab trial results from Norway